BioSpace News Archive

Topline data from the Phase III NATALEE study showed Novartis’ Kisqali met its primary endpoint, reducing the risk of recurrence in early breast cancer.

If management isn’t your strength, there are several upper-level positions that don’t require you to manage others. Here are five high-paying life science jobs that don’t include management.

The FDA approved Pharming’s leniolisib, now to be marketed as Joenja, for the treatment of the ultra-rare disease-activated phosphoinositide 3-kinase delta syndrome, the company announced Friday.

Despite a tough financing market, ArriVent Biopharma closed a $155 million Series B to fund a pivotal Phase III trial of its non-small cell lung cancer asset.

The FDA has granted an advisory committee meeting for BrainStorm Cell Therapeutics’ investigational ALS therapy, NurOwn, the company announced Monday.

UNITY Biotechnology’s lead asset, UBX1325, failed to show non-inferiority to Regeneron’s blockbuster Eylea in a Phase II wet age-related macular degeneration trial.

The AIDS Clinical Trials Group (ACTG), the world’s largest HIV research network, is announcing the publication of “Perspectives on Adherence from the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach with 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment” in the journal Clinical Infectious Diseases.

Secarna Pharmaceuticals GmbH and SciNeuro Pharmaceuticals today announced the signature of a multi-target research and option agreement.

Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the “Company” or “Gemina”) is pleased to announce that it will host a live investor webinar presentation on Thursday, March 30, 2023 at 2:00 PM ET.

nRichDX and OraSure Technologies, Inc., have advanced a commercial collaboration to validate and co-promote their products for researchers developing liquid biopsy applications using first-void urine samples.